Abstract
Mucopolysaccharidosis I consists of three clinical entities with varying degrees of clinical manifestations, all due to the same lysosomal enzyme deficiency, α-l-iduronidase. Hurler (MPS I-H) and Scheie (MPS I-S) syndromes represent phenotypes at the two ends of the clinical spectrum; the Hurler–Scheie syndrome (MPS I-H/S) represents a phenotype of intermediate clinical severity. In most instances, the subtype of MPS I can only be assigned on the basis of clinical criteria, including the rate of progression of symptoms. The incidences for MPS I-H, MPS I-H/S, and MPS I-S are estimated to be 1/76,000–1/144,000, 1/280,000, and 1/840,000–1/1,300,000 live births, respectively.
Access provided by CONRICYT-eBooks. Download reference work entry PDF
Similar content being viewed by others
Keywords
- Hurler-Scheie Syndrome
- Lysosomal Enzyme Deficiency
- Preimplantation Genetic Diagnosis
- Aldurazyme
- Laronidase
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.
Mucopolysaccharidosis I consists of three clinical entities with varying degrees of clinical manifestations, all due to the same lysosomal enzyme deficiency, α-l-iduronidase. Hurler (MPS I-H) and Scheie (MPS I-S) syndromes represent phenotypes at the two ends of the clinical spectrum; the Hurler–Scheie syndrome (MPS I-H/S) represents a phenotype of intermediate clinical severity. In most instances, the subtype of MPS I can only be assigned on the basis of clinical criteria, including the rate of progression of symptoms. The incidences for MPS I-H, MPS I-H/S, and MPS I-S are estimated to be 1/76,000–1/144,000, 1/280,000, and 1/840,000–1/1,300,000 live births, respectively.
Synonyms and Related Disorders
α-l-Iduronidase deficiency; Hurler (MPS I-H); Hurler–Scheie (MPS I-H/S); Scheie (MPS I-S) syndromes
Genetics/Basic Defects
-
1.
Inheritance: autosomal recessive
-
2.
The IDUA gene (Scott et al. 1990)
-
1.
Localized to chromosome 4p16.3, close to the Huntington disease gene
-
2.
Spans 19 kb including 14 exons
-
1.
-
3.
Caused by mutations in the α-l-iduronidase (IDUA) gene (Scott et al. 1992, 1993, 1995; Lee-Chen et al. 1999)
-
1.
Two major alleles (W402X and Q70X) (Bunge et al. 1994; Beesley et al. 2001) and a minor allele (P533R) accounting for over half the MPS I alleles in the Caucasian population.
-
2.
No functional enzymes produced by above-mentioned alleles, giving rise to the severe form of α-l-iduronidase deficiency (MPS I-H).
-
3.
Limited mutations expected to cause the attenuated clinical phenotypes of MPS I-S or MPS I-H/S.
-
4.
One of the mutations resulting in Scheie syndrome is a base substitution in intron 7 that creates a new splice site and produces a frameshift. Since the old splice site is not obliterated, some normal enzymes still can be made to overcome the worst features of MPS I.
-
5.
Most other alleles that lead to MPS I-S or MPS I-H/S carry missense mutations (Lee-Chen and Wang 1997).
-
6.
In the Japanese population studied, MPS I-H/S results from compound heterozygosity of two mutations (704ins5 and R89Q), which, in homozygous form, would give rise to MPS I-H and MPS I-S, respectively (Yamagishi et al. 1996).
-
1.
-
4.
Genotype–phenotype correlations
-
1.
General principle (McKusick et al. 1972; Mueller et al. 1984)
-
1.
Any combination of two severe alleles leads to severe MPS I. A severe allele is one that produces the severe phenotype in either the homozygous state or compound heterozygous state.
-
2.
Intermediate and mild MPS I: usually associated with one severe allele and another allele that permits production of some residual enzyme activity.
-
1.
-
2.
Alleles associated with severe phenotype
-
1.
Two common severe mutations (W402X and Q70X) always confer a severe phenotype whether present in a homozygous state or in a compound heterozygous state.
-
2.
Additional mutations (474-2a-g, A327P, P533R, A75T, L218P).
-
1.
-
3.
Alleles associated with mild phenotype
-
1.
678-7a-g
-
2.
R89Q
-
1.
-
1.
-
5.
Pathophysiology
-
1.
Underlying molecular defect leads to a loss or marked reduction in α-l-iduronidase (IDUA), a lysosomal enzyme involved in the degradation of glycosaminoglycans heparan sulfate and dermatan sulfate.
-
2.
Because of the enzyme deficiency, excessive accumulation of acid mucopolysaccharides (glycosaminoglycans) in the tissue occurs, leading to a wide effect on various systems and remarkable changes in the morphogenesis.
-
1.
Clinical Features
-
1.
Hurler syndrome (MPS I-H)
-
1.
General clinical characteristics
-
1.
The prototype of MPS representing the severe end of clinical spectrum
-
2.
A progressive disorder with multiple organ and tissue involvement, leading to death in childhood
-
3.
Normal phenotype at birth and in early infancy but deteriorates progressively afterward
-
4.
Diagnosis usually made between 4 and 18 months of age
-
5.
Short stature (linear growth stops at 2–3 years of age)
-
6.
Developmental delay by age 12–24 months, with a maximum functional age at the level of 2–4 years, followed by progressive mental deterioration
-
1.
-
2.
Coarse facial features (one of the earliest signs)
-
1.
Ocular hypertelorism
-
2.
Prominent eyes
-
3.
Bushy eyebrows
-
4.
Depressed nasal bridge
-
5.
Wide nostrils
-
6.
Large and thickened lips
-
7.
Large tongue
-
8.
Hypertrophy of the gum and the bony alveolar ridge
-
1.
-
3.
Other craniofacial features
-
1.
A large scaphocephalic head with frontal bossing.
-
2.
Communicating hydrocephalus common after age 2–3 years. Shunting procedures may be beneficial for relieving increased intracranial pressure for some children.
-
3.
Noisy breathing with persistent nasal discharge (chronic rhinorrhea).
-
4.
Upper respiratory and ear infections.
-
1.
-
4.
Ophthalmologic features
-
1.
Progressive clouding of the cornea (the hallmark of the syndrome) beginning at the first year of life, leading to impaired vision
-
2.
Open-angle glaucoma
-
3.
Retinal degeneration resulting in decreased peripheral vision
-
4.
Night blindness
-
1.
-
5.
Auditory features
-
1.
Frequent sensorineural or mixed deafness
-
2.
Contributing factors:
-
1.
Frequent middle ear infection from Eustachian tube dysfunction, caused by storage of glycosaminoglycans within the oropharynx
-
2.
Dysostosis of the ossicles of the middle ear
-
3.
Scarring of the tympanic membrane
-
4.
Damage to the eighth nerve
-
1.
-
1.
-
6.
Cardiovascular features
-
1.
Cardiac valvular disease resulting from storage of mucopolysaccharide in the mitral, aortic, tricuspid, or pulmonary valves, leading to congestive heart failure.
-
2.
Thickened coronary artery valves, leading to angina pectoris and myocardial infarction.
-
3.
Possible fatal cardiomyopathy as a presenting feature for some MPS I infants less than 1 year old. Endocardial fibroelastosis has been noted postmortem in these patients.
-
4.
Aortic stenosis and uncontrolled hypertension (Taylor et al. 1991; Eakins and Kan 2010): although uncommon, aortic stenosis should be included in the differential diagnoses in children with Hurler syndrome and poorly controlled hypertension.
-
1.
-
7.
Gastrointestinal features
-
1.
Protuberant abdomen
-
2.
Progressive hepatosplenomegaly
-
1.
-
8.
Skeletal abnormalities: dysostosis multiplex
-
1.
Short neck
-
2.
Characteristic kyphoscoliosis when attempting to sit
-
3.
Ultimate frank gibbus deformity
-
4.
Stiff joints with limited mobility
-
5.
Claw hands (flexed stubby fingers and broad hands)
-
1.
-
9.
Connective tissue abnormalities
-
1.
Inguinal and umbilical hernias: common findings and usually present at birth
-
2.
Thick skin
-
1.
-
10.
Prognosis
-
1.
Bedridden before the end of the juvenile period
-
2.
Early demise prior to 10 years of age
-
3.
Usual causes of death
-
1.
Obstructive airway disease (Shapiro et al. 1985)
-
2.
Respiratory infection
-
3.
Cardiac complications
-
1.
-
1.
-
1.
-
2.
Scheie syndrome (MPS I-S)
-
1.
The mildest form of MPS I
-
2.
Normal stature
-
3.
Normal intelligence
-
4.
Onset of significant signs usually after 5 years
-
5.
Diagnosis commonly made between 10 and 20 years of age
-
6.
Coarse facial features
-
7.
Deafness in some patients
-
8.
Joint stiffness
-
1.
Claw hands
-
2.
Stiff painful foot
-
1.
-
9.
Carpal tunnel syndrome
-
10.
Pes cavus
-
11.
Genu valgum
-
12.
Ocular manifestations
-
1.
Corneal clouding
-
2.
Glaucoma
-
3.
Retinal degeneration
-
1.
-
13.
Aortic valvular disease (stenosis and regurgitation due to mucopolysaccharide deposits in the valves and chordae tendineae)
-
14.
Obstructive airway disease with sleep apnea in some patients
-
15.
Mild hepatosplenomegaly
-
16.
Mild dysostosis multiplex
-
17.
Less common pachymeningitis cervicalis (compression of the cervical cord by thickened dura) than MPS I-H/S
-
18.
Potential normal life span
-
1.
-
3.
Hurler–Scheie compound (MPS I-H/S)
-
1.
Clinical phenotype intermediate between Hurler and Scheie syndromes (Kajii et al. 1974; Kaibara et al. 1979)
-
2.
Progressive somatic involvement, including dysostosis multiplex, with little or no intellectual dysfunction
-
3.
Age of onset: usually between 3 and 8 years
-
4.
Survival to adulthood: common
-
5.
Deafness
-
6.
Craniofacial features
-
1.
Coarse facial features: less obvious
-
2.
Micrognathia in some patients
-
3.
Broad mouth
-
4.
Square jaw
-
5.
Short neck
-
1.
-
7.
Ophthalmologic features
-
1.
Corneal clouding in all patients
-
2.
Glaucoma
-
3.
Retinal degeneration
-
4.
Optic atrophy
-
1.
-
8.
Valvular heart disease (mitral valve insufficiency) developing by the early to mid-teens
-
9.
Skeletal features
-
1.
Short stature
-
2.
Small thorax
-
3.
Severe joint involvement (stiffness)
-
4.
Kyphoscoliosis
-
5.
Back pain
-
6.
Characteristic claw hand deformity
-
7.
Carpal tunnel syndrome
-
1.
-
10.
Gastrointestinal features
-
1.
Varying degrees of hepatomegaly
-
2.
Hernias
-
1.
-
11.
Pachymeningitis cervicalis (compression of the cervical cord due to mucopolysaccharide accumulation in the dura)
-
12.
Communicating hydrocephalus uncommon in patients who have normal intelligence
-
13.
Spondylolisthesis of the lower spine, leading to spinal cord compression
-
14.
Causes of death (age around teens and 20s)
-
1.
Upper airway obstruction
-
2.
Cardiac involvement
-
1.
-
1.
Diagnostic Investigations
-
1.
Developmental assessment
-
2.
Ophthalmologic examination
-
3.
ECG and echocardiography for cardiovascular status (Nelson et al. 1990)
-
4.
Cranial ultrasound for hydrocephalus
-
5.
Skeletal survey
-
1.
Dysostosis multiplex
-
2.
Skull
-
1.
Large, thickened calvarium
-
2.
Premature closure of lambdoidal and sagittal sutures
-
3.
Shallow orbits
-
4.
Enlarged J-shaped sella
-
5.
Abnormally spaced teeth with dentigerous cysts
-
1.
-
3.
Ribs
-
1.
Oar shaped and narrowed at the vertebral ends
-
2.
Flat/broad at the sternal ends
-
1.
-
4.
Vertebra
-
1.
Beaked anteriorly (anterior hypoplasia) of lumbar vertebrae with kyphosis (an early sign)
-
2.
Scalloped posteriorly
-
3.
Thoracolumbar gibbus, resulting from anterior wedging of the vertebrae
-
4.
Hypoplasia of the odontoid, leading to atlantoaxial subluxation
-
1.
-
5.
Pelvis
-
1.
Poorly formed pelvis
-
2.
Small femoral heads
-
3.
Coxa valga
-
1.
-
6.
Long bones
-
1.
Widened diaphysis of the long bones
-
2.
Lack of normal modeling and tabulation
-
3.
Irregular metaphysis
-
4.
Poorly developed epiphyseal centers
-
5.
Distal ends of the radius and ulna angulate toward each other
-
6.
Claw hands
-
7.
Thickened and bullet-shaped phalanges
-
8.
Coarsening of the trabeculae of the phalanges and metacarpals
-
9.
Proximal narrowing of the metacarpals
-
10.
Marked irregularity and retarded ossification of the carpal bones
-
1.
-
7.
Other bones
-
1.
Short, thickened, and irregular clavicles
-
2.
Shortened and trapezoid-shaped phalanges with widened diaphyses
-
1.
-
1.
-
6.
Biochemical/molecular studies for MPS I-H, MPS I-HS, and MPS I-S
-
1.
Excessive urinary excretion of glycosaminoglycans (dermatan and heparan sulfates): a useful preliminary test
-
2.
Metachromatic staining of fibroblasts and leukocyte inclusions (nonspecific lab findings)
-
3.
Enzyme assay: deficient α-l-iduronidase in WBC, serum, cultured fibroblast, and CSF
-
4.
Accumulation of glycosaminoglycans in cultured fibroblasts correctable by uptake of α-l-iduronidase
-
5.
Mutation analysis or sequence analysis of IUDA gene: possible to identify both IDUA mutations in 95% of patients with MPS I
-
6.
Characterization of gene mutation: worthwhile for phenotype prediction and genetic counseling
-
1.
-
7.
Carrier testing
-
1.
Measurement of α-l-iduronidase enzyme activity: not a reliable method, requiring testing of obligatory carriers within the family first to determine if their levels of IDUA enzyme activity can be distinguishable from the normal
-
2.
Molecular genetic testing of IUDA to identify carriers among at-risk family members when both mutation alleles have been identified in an affected family member
-
1.
Genetic Counseling
-
1.
Recurrence risk
-
1.
Patient’s sib: 25% chance of being affected
-
2.
Patient’s offspring:
-
1.
MPS I-S: not increased unless the spouse is a carrier
-
2.
MPS I-H and MPS I-H/S: not surviving to reproductive age
-
1.
-
1.
-
2.
Prenatal diagnosis from samples of CVS, amniocentesis, and fetal blood (Fratantoni et al. 1969; Ikeno et al. 1981; Muenzer 1986; Young 1992; Fensom and Benson 1994)
-
1.
Enzyme assays (deficient α-l-iduronidase) and increased level of 35 S-sulfate incorporation measured in cultured cells obtained from amniocentesis or CVS for pregnancy at risk
-
2.
Mutation analysis of the IDUA gene in fetal DNA extracted from cells obtained by CVS or amniocentesis if both mutant IDUA alleles have been identified in a previously affected sib or in the parents of the at-risk fetus
-
1.
-
3.
Preimplantation genetic diagnosis (PGD) for at-risk pregnancies: requires prior identification of both IDUA disease-causing mutations in the family
-
4.
Management (Clarke and Heppner 2011; Muenzer and Fisher 2004)
-
1.
Supportive care
-
1.
Early infant stimulation programs
-
2.
Eye care: corneal transplantation successful but donor grafts eventually becoming cloudy
-
3.
Range of motion exercises to preserve joint function
-
4.
Physical therapy
-
1.
-
2.
Orthopedic surgery (Peters et al. 1998; Van Heest et al. 1998)
-
1.
Surgical decompression of the median nerve for carpal tunnel syndrome resulting in various restorations of motor hand activity
-
2.
Trigger digits
-
3.
Genu valgum
-
4.
Kyphoscoliosis
-
5.
Acetabular dysplasia
-
6.
Atlantooccipital stabilization
-
1.
-
3.
Ventriculoperitoneal shunting for hydrocephalus
-
1.
Generally palliative
-
2.
May improve quality of life
-
1.
-
4.
Tracheotomy or high-pressure continuous positive airway pressure with supplemental oxygen
-
5.
Tonsillectomy and adenoidectomy to correct Eustachian tube dysfunction and to decrease upper airway obstruction
-
6.
Cardiovascular care
-
1.
Bacterial endocarditis prophylaxis
-
2.
Valve replacement surgery
-
3.
Management of severe dilated cardiomyopathy: enzyme replacement therapy pre-transplant can improve cardiac function sufficiently to permit safe allogenic hematopoietic stem cell transplantation using myeloablative conditioning (Wiseman et al. 2013)
-
1.
-
7.
Surgical repair of inguinal hernias
-
8.
Early surgical intervention to prevent severe complications from progressive compression of the spinal cord
-
9.
Major anesthetic risks exhibited by patients with MPS I (Walker et al. 1994; Moores et al. 1996)
-
1.
Avoid hyperextension of the neck since dysostosis multiplex can lead to instability of the spine including the atlantoaxial joint.
-
2.
Difficulty in induction of anesthesia due to inability to maintain an adequate airway.
-
3.
Require fiberoptic laryngoscopy for intubation.
-
4.
Slow recovery from anesthesia.
-
5.
Common postoperative airway obstruction.
-
1.
-
10.
Allogenic bone marrow transplantation from an unaffected, HLA-compatible donor (Peters et al. 1996, 1998; Guffon et al. 1998)
-
1.
Beneficial effect: replacement of deficient macrophages by marrow-derived donor macrophages to provide ongoing source of normal enzyme capable of gaining access to the various sites of storage.
-
2.
Slows the course of cognitive decline if the therapy starts before the developmental delay is evident.
-
3.
Improves survival (Whitley et al. 1993), reducing facial coarseness, hepatosplenomegaly, hearing, and normal cardiac function.
-
4.
Skeletal manifestations (Vellodi et al. 1997) and corneal clouding continue to progress despite successful transplantation. Surgeries will be required for the persistent orthopedic problems.
-
5.
Significantly limited by the availability of donors. The immunosuppressive therapy for the prevention of rejection carries significant toxicity.
-
6.
The procedure of the transplantation carries a high risk of morbidity and mortality. Failure to achieve stable engraftment and development of graft-versus-host disease is a significant barrier to successful bone marrow transplantation for many children.
-
7.
Hematopoietic stem cell transplantation: the treatment of choice for a child with Hurler syndrome who is younger than 2 years of age and has minimal or no central nervous system disease (Muenzer 2004).
-
1.
-
11.
Cord blood transplantation (Staba et al. 2004)
-
1.
Use cord blood transplants from partially HLA-matched, unrelated donors.
-
2.
Donors readily available.
-
3.
An excellent source of stem cells for transplantation.
-
4.
Sustained engraftment can be achieved without total-body irradiation in young children.
-
5.
Low incidence for acute graft-versus-host disease (GVHD).
-
6.
Absence of extensive chronic GVHD.
-
7.
As effective as bone marrow transplantation.
-
8.
Unrelated umbilical cord blood transplantation was associated with improved somatic disease and neurodevelopment (Coletti et al. 2015).
-
1.
-
12.
Enzyme replacement therapy (ERT) (Kakkis et al. 2001; Kakkis 2002)
-
1.
An etiology-specific treatment that seeks to address the underlying pathophysiology of MPS I by delivering sufficient IDUA activity to reverse and prevent glycosaminoglycan accumulation (Wraith et al. 2004)
-
2.
Effectiveness depending on the ability of recombinant enzymes injected intravenously to enter cells and localize to the lysosome, the appropriate intracellular site
-
3.
Use of recombinant human α-l-iduronidase (laronidase: Aldurazyme)
-
1.
Aldurazyme®: currently licensed in the USA, Europe, and Canada for use in treating non-CNS manifestations of MPS I. The current dose regime involves premedication with an anti-inflammatory and antihistamine drugs and intravenous weekly infusion of 100 U/kg of Aldurazyme® over 4 h (Clarke and Heppner 2011).
-
2.
Significant reduction in liver size.
-
3.
Increase in height and weight.
-
4.
Decrease in joint restriction.
-
5.
Improvement in breathing (respiratory function) and sleep apnea.
-
6.
Decreased glycosaminoglycan storage.
-
7.
Improvements in cardiopulmonary function, airway obstruction, and joint mobility in Hurler–Scheie syndrome (nonneuronopathic MPS I) (Bijarnia et al. 2009).
-
8.
Recommended for patients with milder or attenuated forms of MPS I. Infusions of recombinant enzyme are a safer alternative for treating the somatic disease and improving the quality of life of such patients. An intravenously administered enzyme is not expected to cross the blood–brain barrier and affect central nervous system disease (Muenzer 2004).
-
9.
Enzyme replacement therapy with laronidase can be used with pre- and peri-hematopoietic stem cell transplant, which is now the gold standard treatment in those patients diagnosed under 2.5 years of age (Jameson et al. 2013).
-
1.
-
1.
-
13.
Hematopoietic stem cell transplantation (HSCT) (Bijarnia et al. 2009): treatment of choice for children <2 years of age with MPS I-H who have minimal or no central nervous disease
-
14.
Combination of ERT followed by HSCT in neuronopathic Hurler syndrome
-
1.
Corrects the enzyme deficiency until endogenous enzyme production is established
-
2.
Reverses airway obstruction and cardiovascular complications, thus reducing mortality and morbidity at the time of transplant
-
1.
-
1.
References
Beesley, C. E., Meaney, C. A., Greenland, G., et al. (2001). Mutational analysis of 85 mucopolysaccharidosis type I families: Frequency of known mutations, identification of 17 novel mutations and in vitro expression of missense mutations. Human Genetics, 109, 503–511.
Bijarnia, S., Shaw, P., Vimpani, A., et al. (2009). Combined enzyme replacement and haematopoietic stem cell transplantation in Hurler syndrome. Journal of Paediatrics and Child Health, 45, 469–472.
Bunge, S., Kleijer, W. J., Steglich, C., et al. (1994). Mucopolysaccharidosis type I: Identification of 8 novel mutations and determination of the frequency of the two common alpha-l-iduronidase mutations (W402X and Q70X) among European patients. Human Molecular Genetics, 3, 861–866.
Clarke L. A., & Heppner, J. (2011). Mucopolysaccharidosis type I. GeneReviews. Retrieved 21 July 2011. Available at: http://www.ncbi.nlm.nih.gov/books/NBK1162/
Coletti, H. Y., Aldenhoven, M., Yelin, K., et al. (2015). Long-term functional outcomes of children with Hurler syndrome treated with unrelated umbilical cord blood transplantation. JIMD Reports, 20, 77–88.
Eakins, C., & Kan, J. H. (2010). Uncontrolled hypertension in a child with Hurler syndrome. Pediatric Radiology, 40(Suppl 1), S120.
Fensom, A. H., & Benson, P. F. (1994). Recent advances in the prenatal diagnosis of the mucopolysaccharidoses. Prenatal Diagnosis, 14, 1–12.
Fratantoni, J. C., Neufeld, E. F., Uhlendorf, B. W., et al. (1969). Intrauterine diagnosis of the Hurler and Hunter syndromes. The New England Journal of Medicine, 280, 686–688.
Guffon, N., Souillet, G., Maire, I., et al. (1998). Follow-up of nine patients with Hurler syndrome after bone marrow transplantation. Journal of Pediatrics, 133, 119–125.
Ikeno, T., Minami, R., Wagatsuma, K., et al. (1981). Prenatal diagnosis of Hurler’s syndrome-biochemical studies on the affected fetus. Human Genetics, 59, 353–359.
Jameson, E., Jones, S., & Wraith, J. E. (2013). Enzyme replacement therapy with laronidase (Aldurazyme) for treating mucopolysaccharidosis type 1. Cochrane Database of Systemic Reviews, 11, 1–15.
Kaibara, N., Eguchi, M., Shibata, K., et al. (1979). Hurler-Scheie phenotype: A report of two pairs of inbred sibs. Human Genetics, 53, 37–41.
Kajii, T., Matsuda, I., Osawa, T., et al. (1974). Hurler/Scheie genetic compound (mucopolysaccharidosis IH/IS) in Japanese brothers. Clinical Genetics, 6, 394–400.
Kakkis, E. D. (2002). Enzyme replacement therapy for the mucopolysaccharide storage disorders. Expert Opinion on Investigational Drugs, 11, 675–685.
Kakkis, E. D., Muenzer, J., Tiller, G. E., et al. (2001). Enzyme-replacement therapy in mucopolysaccharidosis I. The New England Journal of Medicine, 344, 182–188.
Lee-Chen, G. J., & Wang, T. R. (1997). Mucopolysaccharidosis type I: Identification of novel mutations that cause Hurler/Scheie syndrome in Chinese families. Journal of Medical Genetics, 34, 939–941.
Lee-Chen, G. J., Lin, S. P., Tang, Y. F., et al. (1999). Mucopolysaccharidosis type I. Characterization of novel mutations affecting α-l-iduronidase activity. Clinical Genetics, 56, 66–70.
McKusick, V. A., Howell, R. R., Hussels, I. E., et al. (1972). Allelism, nonallelism and genetic compounds among the mucopolysaccharidoses. Lancet, I, 993–996.
Moores, C., Rogers, J. G., McKenzie, I. M., et al. (1996). Anaesthesia for children with mucopolysaccharidoses. Anaesthesia and Intensive Care, 24, 459–463.
Mueller, O. T., Shows, T. B., & Opitz, J. M. (1984). Apparent allelism of the Hurler, Scheie, and Hurler/Scheie syndromes. American Journal of Medical Genetics, 18, 547–556.
Muenzer, J. (1986). Mucopolysaccharidoses. Advances in Pediatrics, 33, 269–302.
Muenzer, J. (2004). The mucopolysaccharidoses: A heterogeneous group of disorders with variable pediatric presentations. Journal of Pediatrics, 144, S27–S34.
Muenzer, J., & Fisher, A. (2004). Advances in the treatment of mucopolysaccharidosis type I. The New England Journal of Medicine, 350, 1932–1934.
Nelson, J., Shields, M. D., & Mulholland, H. C. (1990). Cardiovascular studies in the mucopolysaccharidoses. Journal of Medical Genetics, 27, 94–100.
Peters, C., Balthazor, M., Shapiro, E. G., et al. (1996). Outcome of unrelated donor bone marrow transplantation in 40 children with Hurler syndrome. Blood, 87, 4894–4902.
Peters, C., Shapiro, E. G., Anderson, J., The Storage Disease Collaborative Study Group, et al. (1998). Hurler syndrome: II. Outcome of HLA-genotypically identical sibling and HLA-haploidentical related donor bone marrow transplantation in fifty- four children. Blood, 91, 2601–2608.
Scott, H. S., Ashton, L. J., Eyre, H. J., et al. (1990). Chromosomal localization of the human α-l-iduronidase gene (IDUA) to 4p16.3. American Journal of Human Genetics, 47, 802–807.
Scott, H. S., Guo, X. H., Hopwood, J. J., et al. (1992). Structure and sequence of the human α-l-iduronidase gene. Genomics, 13, 1311–1313.
Scott, H. S., Litjens, T., Nelson, P. V., et al. (1993). Identification of mutations in the alpha-l-iduronidase gene (IDUA) that cause Hurler and Scheie syndromes. American Journal of Human Genetics, 53, 973–986.
Scott, H. S., Bunge, S., Gal, A., et al. (1995). Molecular genetics of mucopolysaccharidosis type I: Diagnostic, clinical, and biological implications. Human Mutation, 6, 288–302.
Shapiro, J., Strome, M., & Crocker, A. C. (1985). Airway obstruction and sleep apnea in Hurler and Hunter syndromes. Annals of Otology, Rhinology and Laryngology, 94, 458–461.
Staba, S. L., Escolar, M. L., Poe, M., et al. (2004). Cord-blood transplants from unrelated donors in patients with Hurler’s syndrome. The New England Journal of Medicine, 350, 1960–1968.
Taylor, D. B., Blaser, S. I., Burrows, P. E., et al. (1991). Arteriopathy and coarctation of the abdominal aorta in children with mucopolysaccharidosis: Imaging findings. AJR. American Journal of Roentgenology, 157, 819–823.
Van Heest, A. E., House, J., Krivit, W., et al. (1998). Surgical treatment of carpal tunnel syndrome and trigger digits in children with mucopolysaccharide storage disorders. The Journal of Hand Surgery (America), 23, 236–243.
Vellodi, A., Young, E. P., Cooper, A., et al. (1997). Bone marrow transplantation for mucopolysaccharidosis type I: Experience of two British centres. Archives of Disease in Childhood, 76, 92–99.
Walker, R. W., Darowski, M., Morris, P., et al. (1994). Anaesthesia and mucopolysaccharidoses. A review of airway problems in children. Anaesthesia, 49, 1078–1084.
Whitley, C. B., Belani, K. G., Chang, P. N., et al. (1993). Long-term outcome of Hurler syndrome following bone marrow transplantation. American Journal of Medical Genetics, 46, 209–218.
Wiseman, D. H., Mercer, J., Tylee, K., et al. (2013). Management of mucopolysaccharidosis type IH (Hurler’s syndrome) presenting in infancy with severe dilated cardiomyopathy: A single institution’s experience. Journal of Inherited Metabolic Diseases, 36, 263–270.
Wraith, J. E., Clarke, L. A., Beck, M., et al. (2004). Enzyme replacement therapy for mucopolysaccharidosis I: A randomized, double-blinded, placebo-controlled, multinational study of recombinant human a-l-iduronidase (laronidase). Journal of Pediatrics, 144, 581–588.
Yamagishi, A., Tomatsu, S., Fukuda, S., et al. (1996). Mucopolysaccharidosis type I: Identification of common mutations that cause Hurler and Scheie syndromes in Japanese populations. Human Mutation, 7, 23–29.
Young, E. P. (1992). Prenatal diagnosis of Hurler disease by analysis of alpha-iduronidase in chorionic villi. Journal of Inherited Metabolic Disease, 15, 224–230.
Author information
Authors and Affiliations
Rights and permissions
Copyright information
© 2017 Springer Science+Business Media LLC
About this entry
Cite this entry
Chen, H. (2017). Mucopolysaccharidosis I (MPS I). In: Atlas of Genetic Diagnosis and Counseling. Springer, New York, NY. https://doi.org/10.1007/978-1-4939-2401-1_161
Download citation
DOI: https://doi.org/10.1007/978-1-4939-2401-1_161
Published:
Publisher Name: Springer, New York, NY
Print ISBN: 978-1-4939-2400-4
Online ISBN: 978-1-4939-2401-1
eBook Packages: MedicineReference Module Medicine